Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Martin Alberer(Ludwig-Maximilians-Universität München), Ulrike Gnad-Vogt(CureVac (Germany)), Henoch S. Hong(CureVac (Germany)), Keyvan Tadjalli Mehr(CureVac (Germany)), Linus Backert(University of Tübingen), Greg Finak(Fred Hutch Cancer Center), Raphaël Gottardo(Fred Hutch Cancer Center), Mihai Alexandru Bica(CureVac (Germany)), A. Garofano(CureVac (Germany)), Sven D. Koch(CureVac (Germany)), Mariola Fotin‐Mleczek(CureVac (Germany)), Ingmar Hoerr(CureVac (Germany)), Ralf Clemens(CureVac (Germany)), Frank von Sonnenburg(Ludwig-Maximilians-Universität München)
Cited by 534
Abstract
Related Papers
No related papers found
Powered by citation graph analysis